For health professionals

• Vaccine preventable diseases

  COVID-19

  Haemophilus influenzae type b (Hib)

  Hepatitis B

  Human papillomavirus

  Influenza

  Measles

  Meningococcal

  Pertussis

  Pneumococcal

  Poliomyelitis

  Rotavirus

  Varicella-zoster (chickenpox)

  Zoster

  Vaccines for Australian adults 

  Vaccinations during pregnancy

• Vaccine safety

  Diabetes and vaccines 

  Hepatitis B and multiple sclerosis 

  Homeopathy and vaccination 

  MMR vaccine, inflammatory bowel disease and autism 

  Resources for addressing patient/parent concerns about immunisation 

  Thiomersal 

  Vaccines, allergy and asthma 

  Vaccine components 

• Vaccination-related clinical resources

  Measles vaccination catch-up guidelines for Australian immunisation providers

  Influenza vaccination post GBS guidelines 

  Injection site reactions

• Vaccines delivery and AIR

  Vaccines from community pharmacy - at a glance

  Enhancing data quality of vaccination encounter recording in practice software and on AIR: tips and tricks

  Supporting and understanding delegations in HPOS to enable access to the Australian Immunisation Register

• ATAGI clinical advices

  COVID-19 

  ATAGI clinical guidance on COVID-19 vaccine in Australia in 2021

  For more statements and clinical advice from ATAGI on COVID-19 vaccination, visit our COVID-19 vaccination program page.

   

  Zoster

  ATAGI statement on the clinical use of zoster vaccine in older adults in Australia

   

  Influenza

  ATAGI advice on influenza and COVID-19 vaccines

  Clinical advice for vaccination providers – 2021 influenza vaccines

  ATAGI advice on seasonal influenza vaccines in 2021

   

  National Immunisation Program Schedule changes - 1 July 2020

  ATAGI clinical advice on changes to recommendations for the use and funding of meningococcal vaccines from 1 July 2020

  ATAGI clinical advice on transitioning to the new hepatitis A vaccination schedule on the National Immunisation Program from 1 July 2020

  ATAGI clinical advice on changes to the vaccine recommendations and funding for people with risk conditions from 1 July 2020

  ATAGI clinical advice on changes to recommendations for the use and funding of pneumococcal vaccines from 1 July 2020

  ATAGI clinical advice on the changes to vaccine recommendations and funding for Aboriginal and Torres Strait Islander people from 1 July 2020

  ATAGI clinical advice on changes to vaccine recommendations for older non-Indigenous adults from 1 July 2020

• COVID-19 vaccination - Resources on thrombosis with thrombocytopenia syndrome following COVID-19 Vaccine AstraZeneca

  COVID-19 Vaccine AstraZeneca is associated with a very rare risk of a condition called thrombosis with thrombocytopenia syndrome, or TTS. 

  TTS involves blood clots (thrombosis) along with low platelet levels (thrombocytopenia), and occurs around 4-28 days after vaccination. It is currently estimated to affect around 6 people per million doses. To date, almost all reported cases were after the first dose of the vaccine. 

  Several resources are available to provide information to immunisation providers about TTS following vaccination with COVID-19 Vaccine AstraZeneca.

  NCIRS COVID-19 vaccines: Frequently asked questions

  We have answered commonly asked questions about thrombosis with thrombocytopenia syndrome following COVID-19 Vaccine AstraZeneca on our COVID-19 vaccines: Frequently asked questions webpage. Access these and other questions and answers about COVID-19 vaccines here.

  ATAGI statements and advices 

  • ATAGI reinforce recommendations on use of COVID-19 vaccines following review of vaccine safety data and benefits - 23 April 2021
  • Information for immunisation providers on thrombosis with thrombocytopenia syndrome (TTS) following COVID-19 vaccination
  • ATAGI immunisation provider guide to obtaining informed consent for COVID-19 vaccine
  • Consent form for COVID-19 vaccination
  • ATAGI clinical guidance on COVID-19 vaccine in Australia in 2021

  Australian Government Department of Health resources 

  • About the AstraZeneca COVID-19 vaccine
  • Information on COVID-19 AstraZeneca vaccine
  • Preparing for COVID-19 vaccination
  • After your AstraZeneca vaccine
  • Patient information sheet on AstraZeneca COVID-19 vaccine and thrombosis with thrombocytopenia syndrome (TTS)
  • Weighing up the potential benefits against risk of harm from COVID-19 Vaccine AstraZeneca

  Therapeutic Good Administration advisories 

  • TGA additional Australian cases of TTS likely linked to vaccine 23 April 2021
  • TGA AstraZeneca ChAdOx1-S COVID-19 vaccine updated safety advisory 9 April 2021

  Others

  • THANZ advisory statement 24 April 2021
  • THANZ ELISA and functional testing request form
  • Brighton Collaboration Interim Case Definition of Thrombosis with Thrombocytopenia Syndrome (TTS) v9.2
  • Guidance from the Expert Haematology Panel (EHP) on Covid-19 Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT) 20 April 2021
  • EMA AstraZeneca’s COVID-19 vaccine 14 April 2021
  • WHO GAVCS review 16 April 2021
  • EMA PRAC meeting highlights 9 April 2021